全文获取类型
收费全文 | 7280篇 |
免费 | 585篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 51篇 |
儿科学 | 242篇 |
妇产科学 | 179篇 |
基础医学 | 826篇 |
口腔科学 | 221篇 |
临床医学 | 657篇 |
内科学 | 1656篇 |
皮肤病学 | 77篇 |
神经病学 | 754篇 |
特种医学 | 203篇 |
外国民族医学 | 1篇 |
外科学 | 956篇 |
综合类 | 113篇 |
一般理论 | 11篇 |
预防医学 | 643篇 |
眼科学 | 262篇 |
药学 | 456篇 |
中国医学 | 5篇 |
肿瘤学 | 571篇 |
出版年
2021年 | 89篇 |
2020年 | 60篇 |
2019年 | 84篇 |
2018年 | 127篇 |
2017年 | 71篇 |
2016年 | 79篇 |
2015年 | 94篇 |
2014年 | 147篇 |
2013年 | 253篇 |
2012年 | 304篇 |
2011年 | 309篇 |
2010年 | 198篇 |
2009年 | 155篇 |
2008年 | 361篇 |
2007年 | 377篇 |
2006年 | 361篇 |
2005年 | 328篇 |
2004年 | 352篇 |
2003年 | 310篇 |
2002年 | 338篇 |
2001年 | 193篇 |
2000年 | 168篇 |
1999年 | 160篇 |
1998年 | 83篇 |
1997年 | 81篇 |
1996年 | 57篇 |
1995年 | 69篇 |
1992年 | 112篇 |
1991年 | 134篇 |
1990年 | 132篇 |
1989年 | 140篇 |
1988年 | 122篇 |
1987年 | 146篇 |
1986年 | 105篇 |
1985年 | 114篇 |
1984年 | 99篇 |
1983年 | 102篇 |
1982年 | 92篇 |
1981年 | 95篇 |
1980年 | 80篇 |
1979年 | 94篇 |
1978年 | 91篇 |
1977年 | 77篇 |
1976年 | 81篇 |
1975年 | 66篇 |
1974年 | 65篇 |
1973年 | 84篇 |
1972年 | 73篇 |
1971年 | 63篇 |
1968年 | 58篇 |
排序方式: 共有7884条查询结果,搜索用时 0 毫秒
1.
2.
3.
The craft of surgery has always relied on the use of instruments. Innovations in surgery have paralleled innovations in instrumentation.
Advances in surgical instrumentation continue today and have enabled huge strides in surgical procedures and outcomes during
this generation. Computers and related technology are now changing the interface between the surgeon and the patient, and
are poised to improve patient outcomes by enhancing the surgeon’s skills and training. The application of computer enhanced
telemanipulators, or “robots”, may specifically enhance operations, for example Heller myotomy, that require good visualization
and precise careful dissection of delicate structures. This review covers the pathophysiology of achalasia and its history
of medical and surgical treatment, leading to modern robotic telesurgical approaches. Improvements in outcome from medical
to standard surgical to robotic telesurgical approaches are discussed. Current operative technique for robotic telesurgical
treatment of achalasia is described and the authors conclude with a glimpse of where, in the future, current research endeavors
will lead us in the treatment of achalasia. 相似文献
4.
Image processing is a critical part of obtaining high-quality digital radiographs. Fortunately, the user of these systems does not need to understand image processing in detail, because the manufacturers provide good starting values. Because radiologists may have different preferences in image appearance, it is helpful to know that many aspects of image appearance can be changed by image processing, and a new preferred setting can be loaded into the computer and saved so that it can become the new standard processing method.Image processing allows one to change the overall optical density of an image and to change its contrast. Spatial frequency processing allows an image to be sharpened, improving its appearance. It also allows noise to be blurred so that it is less visible. Care is necessary to avoid the introduction of artifacts or the hiding of mediastinal tubes. 相似文献
5.
Digital mammography using storage phosphor CR is still in the investigational stage. It is the only digital mammography system that has been tested in preliminary clinical trials with promising early results. Further clinical studies are needed to assess the impact of the limited spatial resolution of storage phosphor technology on its application as a digital screening mammography system. Further studies also are needed to determine the optimum image processing parameters needed in digital mammography. 相似文献
6.
Anatomy of the steroid receptor zinc finger region. 总被引:11,自引:0,他引:11
L P Freedman 《Endocrine reviews》1992,13(2):129-145
7.
8.
Immunological effects of tumor vaccines: II. T cell responses directed against cellular antigens in the viral oncolysates 总被引:1,自引:0,他引:1
Peripheral blood mononuclear cells (PBMC) from patients with epithelial adenocarcinoma of the ovary treated in vivo with tumor vaccines administered as viral oncolysates (VO) exhibited significant proliferative responses in vitro to VO as well as to cellular oncolysates (CO). These responses were dependent on the concentration of VO or CO. VO consisted of lysates from the same ovarian tumor cell lines 2774 and CaOV3 infected in vitro with the avirulent strain of influenza virus A/PR8/34. CO were lysates from the same ovarian tumor cell lines without virus. Depletion experiments with the OKT3 monoclonal antibody plus complement demonstrated that these proliferative responses are T cell specific and under the control of the HLA-D region. Furthermore, these T cell responses are directed against both tumor tumor cellular components and tumor HLA class I molecules. These responses can be detected as early as two weeks after the first intraperitoneal injection of VO and reach a maximum 12-16 weeks after the first application of VO for treatment. PBMC from ovarian patients that received in vivo VO exhibited insignificant proliferative responses to CO prepared from human fibroblasts or tumor cell lines of hematopoietic origin. In contrast, they exhibited significant proliferative responses to CO prepared from a human cervix tumor cell line. These results demonstrate systemic T cell activation by antigens in the tumor vaccines in patients with epithelial ovarian carcinoma after in vivo intraperitoneal administration of VO. 相似文献
9.
Antimurine antibody formation following OKT3 therapy 总被引:1,自引:0,他引:1
T J Schroeder M R First M E Mansour P E Hurtubise S Hariharan F C Ryckman R Munda D B Melvin I Penn W F Ballistreri 《Transplantation》1990,49(1):48-51
OKT3 is an IgG2a murine monoclonal antibody directed against the CD3 antigen receptor of human T lymphocytes. A major concern with OKT3 treatment in solid organ transplant recipients is the development of antimouse antibody, which may preclude retreatment with this agent. We have administered OKT3 on 215 occasions (150 renal, 34 hepatic, 26 cardiac, 5 pancreatic) in 179 patients between April 1982 and December 1988. The mean duration of treatment was 10.5 days (range, 2-22 days). Antimouse antibody data were analyzed on the most recent 133 treatment courses where the antibody status was available pretreatment. Determination of antimouse antibody production was elicited by ELISA technology at days 0, 7, 14, and 28 of OKT3 treatment. Patients were categorized according to the antibody response as follows: (a) absence of antibody; (b) low titer (1:100); or (c) high titer (greater than or equal to 1:1000). Our earlier experience has demonstrated that retreatment with OKT3 is successful in groups a and b. The development of antimurine antibodies was analyzed with regard to the following parameters: (1) The duration of OKT3 treatment; (2) treatment type (prophylactic, primary, or secondary); (3) primary treatment or retreatment; (4) concomitant immunosuppressive regimen (double or triple therapy); (5) dosage of concomitant immunosuppressive drugs; and (6) transplant organ type. The following results were obtained. (1) Duration of treatment had no effect on antibody production (11.0 days in antibody negative and 10.0 days in antibody positive). (2) There was no difference in antibody formation rates for the first treatment of OKT3 when it was used as prophylaxis (26%), primary (19%), or secondary (27%) therapy. (3) Antibody formation rate with first treatment was 29%; with retreatment, patients who were antibody negative following first treatment became positive in 28% of cases, and retreated patients who were low titer positive following first treatment converted to high titer in 57% of cases. (4) Antibody formation was higher in patients receiving double immunosuppressive therapy (36%) than in those receiving triple immunosuppressive therapy (21%) during OKT3 treatment. (5) Concomitant immunosuppression was lower in the antibody-positive group during OKT3 therapy: steroids, 61 mg/day vs. 52 mg/day; azathioprine, 89 mg/day vs. 66 mg/day; CsA, 317 mg/day vs. 186 mg/day. (6) Antibody formation rates were lower in non-renal transplants following first treatment with OKT3 (liver 17%, heart 17%, kidney 28%); this reflects the higher doses of concomitant immunosuppressive therapy used in nonrenal transplants.(ABSTRACT TRUNCATED AT 400 WORDS) 相似文献
10.
Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease 总被引:1,自引:1,他引:0
There is presently a lack of well conducted clinical trials demonstrating any significant benefits of probiotics in humans. With the exception of diarrhoea due to rotavirus infection in children there is little evidence from randomized, double-blind, placebo-controlled studies that bacterial probiotics have a significant beneficial action in preventing diarrhoea of any cause. The yeast Saccharomyces boulardii has been shown to be of benefit in the prevention of antibiotic-associated diarrhoea but not in preventing infection with Clostridium difficile . S. boulardii may also be of benefit in preventing relapse of C. difficile infection. Because of the simplicity of in vitro systems and some animal models, beneficial characteristics of probiotics such as the ability of bacteria to bind to epithelial surfaces are not always transferable to humans. Thus any postulated benefit from consumption of probiotic bacteria should only be accepted as fact after testing in clinical studies.
This review outlines our present knowledge of the mode of action of probiotics and presents the data from clinical trials on their use. 相似文献
This review outlines our present knowledge of the mode of action of probiotics and presents the data from clinical trials on their use. 相似文献